Rituxan Rheumatoid Arthritis sBLA Filing Expected In Late 2005
Executive Summary
The first supplemental BLA filing for Rituxan for the treatment of rheumatoid arthritis is slated for the fourth quarter of 2005, Roche Medical Science Department Head Guido Magni said